| Company | SARC | Symbol |
| Company Name | Sardar Chemical Industries Limited | Company Name |
| Avg EPS | Rs 0.36 | Average of past year end EPS's |
| Avg EPS FV | Rs 3.61 | Fair Value based on average of past year end EPS's |
| EPS | Rs 0.73 | Last four quarters EPS |
| EPS FV | Rs 7.30 | Fair Value based on last four quarters EPS |
| Current Price | Rs 3.90 | Last closing stock price |
| Updated | December 2012 | Data Month/Year |
| Div | Rs 0.50 | Total dividend paid during last four quarters |
| Div FV | Rs 5.00 | Fair value based on total dividend paid during last four quarters |
| Avg Div | Rs 0.11 | Average of yearly dividends paid (including currently paid ones) |
| Avg Div FV | Rs 1.11 | Fair value based on Average of yearly dividends paid (including currently paid ones) |
| Avg | Rs 4.26 | Fair value (averaged of other fair value) |
| Upside | 9.14% | Upside potential (in percentage) based on the above Average. |
| Div Yield | 12.82% | Dividend yield |
| Book Value | Error | Book Value |
| Sector | Chemicals | Sector |
| FV CF/S | Error | Fair Value based on cash flow per share |
| Outstanding Shares | 6,000,000 | Number of Outstanding Shares |
| Current Assets | NA | Currency in Millions of Pakistan Rupees |
| Total Liabilities | NA | Currency in Millions of Pakistan Rupees |
| NCAV/S | #VALUE! | Net Current Asset Value / Share |
| Total Assets | NA | Currency in Millions of Pakistan Rupees |
| Quarter | NA | Data Quarter |
| CfO | NA | CASH FROM OPERATIONS (Millions of Rs) |
| CF/S | #VALUE! | Cash Flow per Share |
| Symbol | SARC | |
| Current Price | Rs 3.90 | |
| Previous Day Price | Rs 3.91 | |
| Daily Return | -0.26% | |
| Price Week Ago | Rs 4.25 | |
| Weekly Return | -8.24% | |
| Price Month Ago | Rs 4.00 | |
| Monthly Return | -2.50% | |
| Price Quarter Ago | Rs 2.66 | |
| Quarterly Return | 46.62% | |
| Price Year Ago | Rs 2.66 | |
| Yearly Return | 46.62% |
Monday, December 3, 2012
SARC - Sardar Chemical Industries Limited - Analysis - 03/12/2012
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment